Intra-Cellular Therapies | Sustainability Performance
Specializes in biopharmaceutical research with a focus on central nervous system disorders. The company develops and commercializes therapies for psychiatric and neurological conditions. Its pipeline includes treatments targeting mood disorders, schizophrenia, and other mental health challenges.
2002
United States
501 - 1,000 employees
Pharmaceuticals
$500M - 1B in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8572
Overallⓘ#1978
in United Statesⓘ#204
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Controversy level
Powered by illuminem
